A Prospective Observational Multi-institutional Study on Invasive Fungal Infections Following Chemotherapy for Acute Myeloid Leukemia (MISFIC Study): A Real World Scenario from India
- 21 Downloads
We performed a prospective multi-centre observational study to understand the incidence of IFI in patients with AML in India with use of anti-fungal prophylaxis. All patients with AML receiving either induction chemotherapy or salvage chemotherapy between November 2014 and February 2016 were included in this prospective observational study from 10 Indian centres. IFI was defined as per the revised EORTC-MSG criteria. Data on type of chemotherapy used, type of anti-fungal prophylaxis used, time to neutrophil recovery, incidence of IFI and survival were collected. Two hundred patients (118 male and 82 females) with a median age of 35 years (range: 2–66) were recruited. One hundred and eighty-six (93%) had newly diagnosed acute myeloid leukemia (AML) while 14 (7%) had relapsed disease. IFI occurred in 53 patients (26.5%) with proven or probable IFI occurring in 17 (8.5%). Use of posaconazole prophylaxis (p = 0.027) was the only factor found to be associated with a reduced incidence of IFI. The overall survival (OS) at 6 weeks and 3 months respectively was similar among patients who had IFI (83.0 ± 5.2%; 81.0 ± 5.4%) as compared to those without IFI (84.4 + 3.0%; 81.4 ± 3.2%). This prospective study reveals a high incidence of IFI in patients undergoing chemotherapy for AML in India. The use of posaconazole prophylaxis was associated with a significantly lower incidence of IFI. Optimal strategies to prevent IFI need to be studied.
KeywordsFungal infection Incidence AML India
This study was funded through an education grant from Merck, Sharpe and Dome (MSD).
Compliance with Ethical Standards
Conflict of interest
The authors declare that they have no conflicts of interest.
Human and Animal Participants
All research involving human participants was performed as per the guidelines established by the Helsinki declaration. All participating institutions obtained ethical clearance from their respective institutions before starting the trial.
All subjects were included only after signing an informed consent.
- 3.Gomes MZR, Mulanovich VE, Jiang Y, Lewis RE, Kontoyiannis DP (2014) Incidence density of invasive fungal infections during primary antifungal prophylaxis in newly diagnosed acute myeloid leukemia patients in a tertiary cancer center, 2009 to 2011. Antimicrob Agents Chemother 58(2):865–873CrossRefPubMedPubMedCentralGoogle Scholar
- 6.Tang JL, Kung HC, Lei WC et al (2015) High incidences of invasive fungal infections in acute myeloid leukemia patients receiving induction chemotherapy without systemic antifungal prophylaxis: a prospective observational study in Taiwan. PLoS ONE 10(6):e0128410CrossRefPubMedPubMedCentralGoogle Scholar
- 7.Cho SY, Lee DG, Choi SM et al (2015) Posaconazole for primary antifungal prophylaxis in patients with acute myeloid leukaemia or myelodysplastic syndrome during remission induction chemotherapy: a single-centre retrospective study in Korea and clinical considerations. Mycoses 58(9):565–571CrossRefPubMedGoogle Scholar
- 8.Korula A, Abraham A, Abubacker FN, Viswabandya A, Lakshmi KM, Abraham OC, Rupali P, Varghese GM, Michael JS, Srivastava A, Mathews V, George B (2017) Invasive fungal infection following chemotherapy for acute myeloid leukaemia—experience from a developing country. Mycoses 60(10):686–691CrossRefPubMedGoogle Scholar
- 11.Ananda-Rajah MR, Grigg A, Downey MT et al (2012) Comparative clinical effectiveness of prophylactic voriconazole/posaconazole to fluconazole/itraconazole in patients with acute myeloid leukemia/myelodysplastic syndrome undergoing cytotoxic chemotherapy over a 12- year period. Haematologica 97(3):459–463CrossRefPubMedPubMedCentralGoogle Scholar
- 14.Cornely OA, Cuenca-Estrella M, Meis JF et al (2014) European Society of Clinical Microbiology and Infectious Diseases (ESCMID) fungal infection study group (EFISG) and European Confederation of Medical Mycology (ECMM) 2013 joint guidelines on diagnosis and management of rare and emerging fungal diseases. Clin Microbiol Infect 20:1–4CrossRefPubMedGoogle Scholar
- 18.De Pauw B, Walsh TJ, Donnelly JP et al (2008) Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 46(12):1813–1821CrossRefPubMedPubMedCentralGoogle Scholar
- 21.Tormo M, Pérez-Martínez A, Calabuig M, Hernández-Boluda JC, Amat P, Navarro D, Solano C (2018) Primary prophylaxis of invasive fungal infections with posaconazole or itraconazole in patients with acute myeloid leukaemia or high-risk myelodysplastic syndromes undergoing intensive cytotoxic chemotherapy: a real-world comparison. Mycoses 61(3):206–212CrossRefPubMedGoogle Scholar
- 22.Dahlén T, Kalin M, Cederlund K, Nordlander A, Björkholm M, Ljungman P, Blennow O (2016) Decreased invasive fungal disease but no impact on overall survival by posaconazole compared to fluconazole prophylaxis: a retrospective cohort study in patients receiving induction therapy for acute myeloid leukaemia/myelodysplastic syndromes. Eur J Haematol 96(2):175–180CrossRefPubMedGoogle Scholar